Dr. Morse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1504 Taub Loop
Houston, TX 77030Phone+1 713-566-3377
Summary
- Dr. Meroe Morse is an internist in Houston, TX and is affiliated with Harris Health System. She received her medical degree from Tulane University School of Medicine and has been in practice 6 years. She also speaks multiple languages, including Spanish. She specializes in complementary and integrative medicine and is experienced in hypertension, complementary and integrative medicine, diabetes mellitus, cardiology, and geriatrics.
Clinical Expertise
- Diabetes mellitus, Cardiology, Geriatrics, Thyroid disease, Hyperlipidemia, Hypertension, Complementary and integrative medicine, Cerebrovascular disease
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Integrative Medicine, 2017 - 2019
- NYU Grossman School of MedicineResidency, Internal Medicine, 2011 - 2014
- Tulane University School of MedicineClass of 2011
- Columbia Universitycertificate, Post-Baccalaureate Pre-Medical Sciences, 2004 - 2006
- Brown UniversityBA, Biology, 1997 - 2001
Certifications & Licensure
- FL State Medical License 2024 - Present
- GA State Medical License 2023 - 2026
- TX State Medical License 2014 - 2026
- WA State Medical License 2023 - 2026
- AL State Medical License 2023 - 2025
- AZ State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- American Board of Internal Medicine Internal Medicine
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsAddressing Patient Requests to Add Dietary Supplements to Their Cancer Care-A Suggested Approach.Moshe Frenkel, Meroe B Morse, Santhosshi Narayanan
Nutrients. 2023-12-07 - 319 citationsRandomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-...Leonard B. Saltz, Heinz-Josef Lenz, Hedy L. Kindler, Howard S. Hochster, Scott Wadler
Journal of Clinical Oncology. 2007-10-10 - 149 citationsPhase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancerNancy E. Kemeny, William R. Jarnagin, Philip B. Paty, Mithat Gonen, Lawrence H. Schwartz
Journal of Clinical Oncology. 2005-08-01
Professional Memberships
- The Beryl InstituteMember
- Member
- The Arnold P. Gold Humanism Honor SocietyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: